Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04398849




Registration number
NCT04398849
Ethics application status
Date submitted
18/05/2020
Date registered
21/05/2020
Date last updated
9/03/2023

Titles & IDs
Public title
Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)
Scientific title
Immunisation for Adolescents Against Serious Communicable Diseases
Secondary ID [1] 0 0
Menzies HREC/2019-3507-V1.7
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gonorrhea 0 0
Meningococcal Disease 0 0
Condition category
Condition code
Infection 0 0 0 0
Sexually transmitted infections
Reproductive Health and Childbirth 0 0 0 0
Other reproductive health and childbirth disorders
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Other - Licenced 4CMenB Vaccine

14-19 year olds residing in the Northern Territory - All consenting 14-19 year olds residing in the Northern Territory in 2020-2021


Treatment: Other: Licenced 4CMenB Vaccine
Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
1. 4CMenB vaccination status in the population with gonorrhoea compared to randomly selected Chlamydia controls (Case-control)
Timepoint [1] 0 0
3 years
Primary outcome [2] 0 0
Effect of 4CMenB vaccine on carriage of all N.meningitidis
Timepoint [2] 0 0
12 months
Secondary outcome [1] 0 0
4CMenB vaccination status in the population with gonorrhoea compared to randomly selected controls from the Australian Immunisation Register (Case-control)
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
4CMenB vaccination status in the population with gonorrhoea compared to the general population (Screening method)
Timepoint [2] 0 0
3 years
Secondary outcome [3] 0 0
All laboratory confirmed notifications of gonorrhoea in the six years preceding 4CMenB vaccination compared to three years post vaccination (Interrupted time series analysis)
Timepoint [3] 0 0
7 years
Secondary outcome [4] 0 0
All laboratory confirmed notifications of gonorrhoea in 15-19 year olds in the vaccinated population compared to the unvaccinated population
Timepoint [4] 0 0
3 years
Secondary outcome [5] 0 0
All laboratory confirmed notifications of gonorrhoea in the vaccinated population compared to the unvaccinated population stratified by gender
Timepoint [5] 0 0
3 years
Secondary outcome [6] 0 0
All laboratory confirmed notifications of gonorrhoea in the vaccinated population compared to the unvaccinated population stratified by geographical location (regional/remote/very remote)
Timepoint [6] 0 0
3 years
Secondary outcome [7] 0 0
Effect of 4CMenB vaccine on carriage of all disease causing N.meningitidis
Timepoint [7] 0 0
12 months
Secondary outcome [8] 0 0
Effect of 4CMenB vaccine on carriage of each disease causing N.meningitidis
Timepoint [8] 0 0
12 months
Secondary outcome [9] 0 0
Effect of 4CMenB vaccine on carriage of all non-groupable N.meningitidis
Timepoint [9] 0 0
12 months
Secondary outcome [10] 0 0
Effect of 4CMenB vaccine on acquisition of all N. meningitidis
Timepoint [10] 0 0
12 months
Secondary outcome [11] 0 0
Effect of 4CMenB impact on Group B IMD (Interrupted time series)
Timepoint [11] 0 0
3 years
Secondary outcome [12] 0 0
Effect of 4CMenB effectiveness on Group B IMD (screening method)
Timepoint [12] 0 0
3 years
Secondary outcome [13] 0 0
Effect of 4CMenB effectiveness on Group B IMD (case-control method)
Timepoint [13] 0 0
3 years
Secondary outcome [14] 0 0
Risk factors for gonorrhoea
Timepoint [14] 0 0
12 months
Secondary outcome [15] 0 0
Risk factors for carriage of all N.meningitidis
Timepoint [15] 0 0
12 months
Secondary outcome [16] 0 0
Risk for carriage of disease causing genogroups of N.meningitidis
Timepoint [16] 0 0
12 months
Secondary outcome [17] 0 0
Cost effectiveness of the 4CMenB vaccine
Timepoint [17] 0 0
3 years

Eligibility
Key inclusion criteria
All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
Minimum age
14 Years
Maximum age
19 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Anaphylaxis following any component of Bexsero® vaccine
* Previous receipt of MenB vaccine (Bexsero® (Previous receipt of MenNZBTM is allowed).
* Known pregnancy
* Clinical conditions representing a contraindication to intramuscular vaccination and venipuncture
* Any clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/03/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2024
Actual
Sample size
Target
7100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Northern Territory - Central Australia
Recruitment postcode(s) [1] 0 0
- Central Australia

Funding & Sponsors
Primary sponsor type
Other
Name
University of Adelaide
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The University of New South Wales
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Menzies School of Health Research
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
University of Sydney
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
The University of Western Australia
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Government body
Name [5] 0 0
Northern Territory Government of Australia
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
SA Health
Address [6] 0 0
Country [6] 0 0
Other collaborator category [7] 0 0
Other
Name [7] 0 0
The University of Queensland
Address [7] 0 0
Country [7] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study aims to implement a targeted 4CMenB immunisation program in young people aged 14-19 years in the Northern Territory (NT). As part of the NT program consenting 14-19 year olds will receive 2 doses of the licensed 4CMenB vaccine. An oropharyngeal swab will be collected on the same day as the first dose of the vaccine and 12 months later to assess carriage of Neisseria meningitidis. The first swab will assess baseline carriage prevalence among 14-19 year olds in the NT. The swab taken 12 months later will provide data on the change in carriage that may occur after implementation of the immunisation program. Emerging evidence suggests that the 4CMenB vaccine may be protective against gonorrhea. Therefore, vaccine effect (impact and effectiveness) against both invasive meningococcal disease (IMD) and gonorrhea in the NT will be assessed using data from the above study comparing notifications between vaccinated and unvaccinated as well as comparing pre and post implementation periods.
Trial website
https://clinicaltrials.gov/study/NCT04398849
Trial related presentations / publications
Marshall HS, Andraweera PH, Ward J, Kaldor J, Andrews R, Macartney K, Richmond P, Krause V, Koehler A, Whiley D, Giles L, Webby R, D'Antoine H, Karnon J, Baird R, Lawrence A, Petousis-Harris H, De Wals P, Greenwood-Smith B, Binks M, Whop L. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol. Vaccines (Basel). 2022 Feb 16;10(2):309. doi: 10.3390/vaccines10020309.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Helen Marshall, MBBS,MD,MPH
Address 0 0
Country 0 0
Phone 0 0
+61 8 8161 8115
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04398849